Alterity Therapeutics (ATHE) Income from Continuing Operations (2009 - 2024)
Alterity Therapeutics (ATHE) posted quarterly Income from Continuing Operations of 12755923.06 for Q2 2024, down 36.64% year-over-year from 20132903.52 in Q3 2023, and down 36.64% quarter-over-quarter from 9335327.2 in Q2 2023.
Alterity Therapeutics (ATHE) Income from Continuing Operations (2009 - 2024) Analysis & Trends
Alterity Therapeutics' Income from Continuing Operations history runs 9 years deep, the most recent figure standing at 12755923.06 for Q2 2024.
- In Q2 2024, Income from Continuing Operations fell 36.64% year-over-year to 12755923.06; the TTM figure through Jun 2024 stood at 35270321.65 (down 12.56% YoY), while the FY2025 annual figure was 7823457.08, up 38.81% from the prior year.
- Income from Continuing Operations for Q2 2024 stood at 12755923.06, down from 9335327.2 in the prior quarter.
- The five-year high for Income from Continuing Operations was 9325709.73 in Q2 2022, with the low at 12755923.06 in Q2 2024.
- The 3-year median for Income from Continuing Operations is 9335327.2 (2023), against an average of 10472320.0.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations slipped 0.1% in 2023, then slumped 36.64% in 2024.
- Alterity Therapeutics' Income from Continuing Operations stood at 9325709.73 in 2022, then decreased by 0.1% to 9335327.2 in 2023, then plunged by 36.64% to 12755923.06 in 2024.
- Business Quant data shows ATHE's Income from Continuing Operations at 12755923.06 in Q2 2024, 9335327.2 in Q2 2023, and 9325709.73 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Alterity Therapeutics | 48.56 Mn | 16.26 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -12.76 Mn |
| Jun 30, 2023 | -9.34 Mn |
| Jun 30, 2022 | -9.33 Mn |
| Dec 31, 2019 | -3.85 Mn |
| Jun 30, 2019 | -8.82 Mn |
| Dec 31, 2018 | -3.83 Mn |
| Jun 30, 2018 | -6.38 Mn |
| Dec 31, 2017 | -2.78 Mn |
| Jun 30, 2017 | -5.38 Mn |
| Dec 31, 2016 | -2.74 Mn |
| Jun 30, 2010 | -4.34 Mn |
| Jun 30, 2009 | -5.71 Mn |